AAPL326.57+11.23 (+3.56%) ▲|ABBV255.00+4.09 (+1.63%) ▲|ABT103.36-1.87 (-1.78%) ▼|ACN177.91+2.11 (+1.20%) ▲|ADBE248.83-6.03 (-2.37%) ▼|AMAT454.01-14.84 (-3.17%) ▼|AMD503.60-17.50 (-3.36%) ▼|AMGN382.47-8.80 (-2.25%) ▼|AMT172.98-2.45 (-1.40%) ▼|AMZN251.89-0.51 (-0.20%) ▼|AVGO360.83-3.55 (-0.97%) ▼|AXP320.71-1.09 (-0.34%) ▼|BA204.80-1.62 (-0.78%) ▼|BAC62.56-0.11 (-0.18%) ▼|BKNG174.33+0.90 (+0.52%) ▲|BLK1,062.40-9.63 (-0.90%) ▼|BMY63.75-0.66 (-1.02%) ▼|BNY162.59+0.08 (+0.05%) ▲|BRK-B507.00+0.28 (+0.06%) ▲|C138.50+0.70 (+0.51%) ▲|CAT805.00-10.56 (-1.29%) ▼|CL87.90-0.13 (-0.15%) ▼|CMCSA25.17+0.58 (+2.36%) ▲|COF207.11-3.75 (-1.78%) ▼|COP137.04+0.51 (+0.37%) ▲|COST902.38-0.22 (-0.02%) ▼|CRM243.00-1.16 (-0.48%) ▼|CSCO107.44-1.99 (-1.82%) ▼|CVS95.29-0.09 (-0.09%) ▼|CVX212.76-1.05 (-0.49%) ▼|DE677.94+0.73 (+0.11%) ▲|DHR200.53-4.32 (-2.11%) ▼|DIS105.82+1.64 (+1.57%) ▲|DUK119.37-1.06 (-0.88%) ▼|EMR148.37-1.97 (-1.31%) ▼|FDX311.80+2.61 (+0.84%) ▲|GD354.25+1.58 (+0.45%) ▲|GE324.15-1.27 (-0.39%) ▼|GEV923.91-27.13 (-2.85%) ▼|GILD144.81-0.84 (-0.58%) ▼|GM86.12+2.36 (+2.82%) ▲|GOOG330.39+2.01 (+0.61%) ▲|GOOGL332.60+1.95 (+0.59%) ▲|GS1,019.77-9.01 (-0.88%) ▼|HD305.69-4.76 (-1.53%) ▼|HON202.18-2.75 (-1.34%) ▼|IBM234.02-5.92 (-2.47%) ▼|INTC100.32-5.92 (-5.57%) ▼|INTU312.77-1.17 (-0.37%) ▼|ISRG360.46+7.22 (+2.04%) ▲|JNJ266.35-0.73 (-0.27%) ▼|JPM353.56-1.15 (-0.32%) ▼|KO87.83+0.28 (+0.32%) ▲|LIN461.62-5.03 (-1.08%) ▼|LLY1,123.00-1.21 (-0.11%) ▼|LMT530.12+5.66 (+1.08%) ▲|LOW196.59-2.01 (-1.01%) ▼|LRCX298.01-17.83 (-5.65%) ▼|MA565.37-2.13 (-0.38%) ▼|MCD253.05-0.43 (-0.17%) ▼|MDLZ62.47+0.05 (+0.08%) ▲|MDT91.62-0.27 (-0.29%) ▼|META644.38-9.31 (-1.42%) ▼|MMM162.86-1.54 (-0.94%) ▼|MO68.79+0.90 (+1.33%) ▲|MRK144.71-2.82 (-1.91%) ▼|MS212.66-2.69 (-1.25%) ▼|MSFT492.44+0.79 (+0.16%) ▲|MU977.41-50.36 (-4.90%) ▼|NEE82.44-0.21 (-0.25%) ▼|NFLX76.01-0.02 (-0.03%) ▼|NKE36.62-0.73 (-1.95%) ▼|NOW131.17+0.06 (+0.05%) ▲|NVDA218.36-5.31 (-2.37%) ▼|ORCL152.94-8.69 (-5.38%) ▼|PEP136.65-0.04 (-0.03%) ▼|PFE27.65-0.13 (-0.47%) ▼|PG142.97+0.33 (+0.23%) ▲|PLTR165.86-3.67 (-2.16%) ▼|PM189.77+4.06 (+2.19%) ▲|QCOM176.88+0.48 (+0.27%) ▲|RTX198.12+0.57 (+0.29%) ▲|SBUX99.22-0.82 (-0.82%) ▼|SCHW107.33+0.79 (+0.74%) ▲|SO87.75-0.59 (-0.67%) ▼|SPG204.67+0.14 (+0.07%) ▲|T25.55+0.40 (+1.59%) ▲|TMO603.18-2.51 (-0.41%) ▼|TMUS177.16-0.18 (-0.10%) ▼|TSLA363.56-4.25 (-1.16%) ▼|TXN258.82-2.77 (-1.06%) ▼|UBER72.56+1.48 (+2.08%) ▲|UNH388.28-4.78 (-1.22%) ▼|UNP285.78+1.04 (+0.37%) ▲|UPS99.97+0.75 (+0.76%) ▲|USB62.41+0.30 (+0.48%) ▲|V367.21-0.18 (-0.05%) ▼|VZ49.97+0.23 (+0.46%) ▲|WFC89.45-0.22 (-0.25%) ▼|WMT105.73-0.10 (-0.09%) ▼|XOM165.23+1.00 (+0.61%) ▲|AAPL326.57+11.23 (+3.56%) ▲|ABBV255.00+4.09 (+1.63%) ▲|ABT103.36-1.87 (-1.78%) ▼|ACN177.91+2.11 (+1.20%) ▲|ADBE248.83-6.03 (-2.37%) ▼|AMAT454.01-14.84 (-3.17%) ▼|AMD503.60-17.50 (-3.36%) ▼|AMGN382.47-8.80 (-2.25%) ▼|AMT172.98-2.45 (-1.40%) ▼|AMZN251.89-0.51 (-0.20%) ▼|AVGO360.83-3.55 (-0.97%) ▼|AXP320.71-1.09 (-0.34%) ▼|BA204.80-1.62 (-0.78%) ▼|BAC62.56-0.11 (-0.18%) ▼|BKNG174.33+0.90 (+0.52%) ▲|BLK1,062.40-9.63 (-0.90%) ▼|BMY63.75-0.66 (-1.02%) ▼|BNY162.59+0.08 (+0.05%) ▲|BRK-B507.00+0.28 (+0.06%) ▲|C138.50+0.70 (+0.51%) ▲|CAT805.00-10.56 (-1.29%) ▼|CL87.90-0.13 (-0.15%) ▼|CMCSA25.17+0.58 (+2.36%) ▲|COF207.11-3.75 (-1.78%) ▼|COP137.04+0.51 (+0.37%) ▲|COST902.38-0.22 (-0.02%) ▼|CRM243.00-1.16 (-0.48%) ▼|CSCO107.44-1.99 (-1.82%) ▼|CVS95.29-0.09 (-0.09%) ▼|CVX212.76-1.05 (-0.49%) ▼|DE677.94+0.73 (+0.11%) ▲|DHR200.53-4.32 (-2.11%) ▼|DIS105.82+1.64 (+1.57%) ▲|DUK119.37-1.06 (-0.88%) ▼|EMR148.37-1.97 (-1.31%) ▼|FDX311.80+2.61 (+0.84%) ▲|GD354.25+1.58 (+0.45%) ▲|GE324.15-1.27 (-0.39%) ▼|GEV923.91-27.13 (-2.85%) ▼|GILD144.81-0.84 (-0.58%) ▼|GM86.12+2.36 (+2.82%) ▲|GOOG330.39+2.01 (+0.61%) ▲|GOOGL332.60+1.95 (+0.59%) ▲|GS1,019.77-9.01 (-0.88%) ▼|HD305.69-4.76 (-1.53%) ▼|HON202.18-2.75 (-1.34%) ▼|IBM234.02-5.92 (-2.47%) ▼|INTC100.32-5.92 (-5.57%) ▼|INTU312.77-1.17 (-0.37%) ▼|ISRG360.46+7.22 (+2.04%) ▲|JNJ266.35-0.73 (-0.27%) ▼|JPM353.56-1.15 (-0.32%) ▼|KO87.83+0.28 (+0.32%) ▲|LIN461.62-5.03 (-1.08%) ▼|LLY1,123.00-1.21 (-0.11%) ▼|LMT530.12+5.66 (+1.08%) ▲|LOW196.59-2.01 (-1.01%) ▼|LRCX298.01-17.83 (-5.65%) ▼|MA565.37-2.13 (-0.38%) ▼|MCD253.05-0.43 (-0.17%) ▼|MDLZ62.47+0.05 (+0.08%) ▲|MDT91.62-0.27 (-0.29%) ▼|META644.38-9.31 (-1.42%) ▼|MMM162.86-1.54 (-0.94%) ▼|MO68.79+0.90 (+1.33%) ▲|MRK144.71-2.82 (-1.91%) ▼|MS212.66-2.69 (-1.25%) ▼|MSFT492.44+0.79 (+0.16%) ▲|MU977.41-50.36 (-4.90%) ▼|NEE82.44-0.21 (-0.25%) ▼|NFLX76.01-0.02 (-0.03%) ▼|NKE36.62-0.73 (-1.95%) ▼|NOW131.17+0.06 (+0.05%) ▲|NVDA218.36-5.31 (-2.37%) ▼|ORCL152.94-8.69 (-5.38%) ▼|PEP136.65-0.04 (-0.03%) ▼|PFE27.65-0.13 (-0.47%) ▼|PG142.97+0.33 (+0.23%) ▲|PLTR165.86-3.67 (-2.16%) ▼|PM189.77+4.06 (+2.19%) ▲|QCOM176.88+0.48 (+0.27%) ▲|RTX198.12+0.57 (+0.29%) ▲|SBUX99.22-0.82 (-0.82%) ▼|SCHW107.33+0.79 (+0.74%) ▲|SO87.75-0.59 (-0.67%) ▼|SPG204.67+0.14 (+0.07%) ▲|T25.55+0.40 (+1.59%) ▲|TMO603.18-2.51 (-0.41%) ▼|TMUS177.16-0.18 (-0.10%) ▼|TSLA363.56-4.25 (-1.16%) ▼|TXN258.82-2.77 (-1.06%) ▼|UBER72.56+1.48 (+2.08%) ▲|UNH388.28-4.78 (-1.22%) ▼|UNP285.78+1.04 (+0.37%) ▲|UPS99.97+0.75 (+0.76%) ▲|USB62.41+0.30 (+0.48%) ▲|V367.21-0.18 (-0.05%) ▼|VZ49.97+0.23 (+0.46%) ▲|WFC89.45-0.22 (-0.25%) ▼|WMT105.73-0.10 (-0.09%) ▼|XOM165.23+1.00 (+0.61%) ▲|
26.3 C
New York
Friday, September 11, 2026

Tag: trends

Comprehensive Lewy Body Dementia Market Analysis of Evolving Trends and Anticipated Growth Trajectory During the Forecast Period (2025-2034) | DelveInsight

According to DelveInsight's analysis, the Lewy body dementia market is anticipated to increase during the forecast period (2025–2034), owing to the launch of emerging...

Anti-GPC3 Therapies Market Gains Traction with Key Players Advancing Pipeline for Hepatocellular Carcinoma, Non-Small Cell Lung Cancer, Gastric Cancer, and Others | DelveInsight

The anti-GPC3 targeted therapies market is expected to witness growth in the coming years, driven by the increasing incidence of cancer cases, clinical pipeline...

Anti-GPC3 Therapies Market Gains Traction with Key Players Advancing Pipeline for Hepatocellular Carcinoma, Non-Small Cell Lung Cancer, Gastric Cancer, and Others | DelveInsight

The anti-GPC3 targeted therapies market is expected to witness growth in the coming years, driven by the increasing incidence of cancer cases, clinical pipeline...

Ramaco Releases Summary of Independent Preliminary Economic Assessment Report from Fluor Corporation

LEXINGTON, Ky., July 10, 2025 /PRNewswire/ -- Ramaco Resources, Inc. (NASDAQ: METC, METCB) ("Ramaco" or the "Company") today announced that it has released a...

Avient Announces Quarterly Dividend

CLEVELAND, July 10, 2025 /PRNewswire/ -- The Board of Directors of Avient Corporation (NYSE: AVNT), an innovator of materials solutions, has declared a quarterly cash...

Flutter secures 100% ownership of FanDuel through new agreement with Boyd

NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) -- Flutter Entertainment (NYSE: FLUT; LSE: FLTR) (“Flutter”) the world’s leading online sports betting and iGaming operator today announces the extension of its long-term strategic partnership with Boyd Gaming Corporation (“Boyd”) to 2038 and the buyout of Boyd’s 5% stake in FanDuel Group (“FanDuel”), together “the Agreement”.

BOYD GAMING TO SELL FANDUEL INTEREST FOR $1.755 BILLION

All-Cash Transaction Unlocks Significant, Unrealized Value for Boyd ShareholdersBoyd, FanDuel Extend Market-Access Agreements through 2038 LAS VEGAS, July 10, 2025 /PRNewswire/ -- Boyd Gaming Corporation (NYSE:...

NKGen Biotech Administers First Dose of Troculeucel to Alzheimer’s Patient Who Continued to Decline Cognitively While on Prior Amyloid-Targeting Therapy

SANTA ANA, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced the administration of the first dose of troculeucel, an expanded autologous NK cell therapy, under a single compassionate use, Investigational New Drug (“IND”) authorization cleared by the U.S. Food and Drug Administration (“FDA”), to a patient with mild-stage Alzheimer’s disease who exhibited continued cognitive decline despite ongoing treatment with lecanemab, an amyloid targeting therapy. This exploratory work is being conducted in collaboration with Anita Fletcher, M.D., a board-certified neurologist with specialized training in neuroimmunology, who also serves as Director of Neuroscience Clinical Research at AdventHealth Neuroscience Institute in Orlando, Florida.

Aritzia Reports First Quarter Fiscal 2026 Financial Results

VANCOUVER, BC, July 10, 2025 /PRNewswire/ - Aritzia Inc. (TSX: ATZ) ("Aritzia", the "Company", "we" or "our"), a design house with an innovative global...

Aritzia Reports First Quarter Fiscal 2026 Financial Results

VANCOUVER, BC, July 10, 2025 /CNW/ - Aritzia Inc. (TSX: ATZ) ("Aritzia", the "Company", "we" or "our"), a design house with an innovative global...

Iovance Biotherapeutics Appoints Marc R. Theoret, M.D. as Senior Vice President, Regulatory Strategy

SAN CARLOS, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced the appointment of Marc. R Theoret, M.D. to assume the newly created position of Senior Vice President, Regulatory Strategy, where he will focus on clinical regulatory strategy for Iovance’s pipeline. Effective immediately, Dr. Theoret will report to Dr. Raj K. Puri, M.D., Ph.D., Chief Regulatory Officer.

Fewer Than Half of Americans See U.S. Healthcare in a Positive Light: Consumers Call for a More Affordable, Accessible, and Trustworthy System

Americans express persistent frustration over high costs and declining trust in the U.S healthcare system. NASHVILLE, Tenn., July 10, 2025 /PRNewswire/ -- As debate over...

QNET Unveils Wellness Breakthroughs and Global Empowerment at V-Malaysia 2025

Over 8,000 global entrepreneurs gather in Penang for five days of wellness innovation and mentorship. HONG KONG, July 11, 2025 /PRNewswire/ -- QNET kicked off...

The VinFast VF 9 Becomes Uncompromising Comfort for the Modern Family

The VF 9 offers authentic comfort across its three rows of seating, perfectly suiting families with more than four members or those frequently traveling...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsTrends